1Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology, 1996, 84 : 732-747.
2Practice guidelines for Perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task force on Perioperative Blood Transfusion and Adjuvant Therapies, Anesthesiology, 2006, 105 : 198-208.
5Gandhi SD, Weiskopf RB, Jungheinrich C, et al. Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl startch 130/0. 4) or hetastarch. Anesthesiology, 2007,106:1120-1127.
6Tian J,Lin X, Guan R, et al. The effects of hydroxyethyl starch on lung capillary permeability in endotoxic rats and possible mechanisms. Anesth Analg, 2004, 98: 768-774.
7Von Roten I, Madjdpour C, Frascarolo P, et al. Molar substitution and C2/C6 ratio of hydroxyethyl starch., influence on blood coagulation. BrJ Anaesth, 2006, 96: 455-463.
8Boldt J, Haisch G, Suttner S, et al. Effects of a new modified,balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation. Br J Anaesth, 2002, 89: 722-728.
9Kozek-Langenecker SA. Effects of hydroxyethyl starch solutions on homeostasis. Anesthesiology, 2005, 103: 654-660.
5ASA Task Force. Practice guidelines for perioperative blood transfusion and adjuvant therapies . Anesthesiol, 2006,105 : 198- 208.
6Clark AD, Gordon WC, Walker ID, et al. ' Last-ditch' use of recombinant factor Ⅶ a in patients with massive hemorrhage is ineffective. Vox Sang, 2004,86 : 120-124.
